Carolyn Mountford DPhil, Presenter: Nothing to Disclose

Peter Stanwell BS, Abstract Co-Author: Nothing to Disclose

Alan Ferrier, Abstract Co-Author: Nothing to Disclose

Roger Bourne PhD, Abstract Co-Author: Nothing to Disclose

James Christie, Abstract Co-Author: Nothing to Disclose

Rebecca Chin, Abstract Co-Author: Nothing to Disclose

Peter Russell, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

Undertake in vivo spectroscopy and imaging of the ovary at 3T. This will be compared with spectroscopy at 8.5T done on biopsies collected intraoperatively.

Patients were recruited from the Gynaecological Oncology Unit at Royal North Shore Hospital. In vivo MR data was collected on a 3T Magnetom system (Siemens Germany) using a USA Instruments torso phased-array coil. Ovaries were identified on T2-weighted (TE/TR 98/4000ms, FOV 22-cm, matrix 266x512, 3-mm slice thickness, iPAT 2) axial and coronal images. 2D CSI (TE/TR 135/1380-ms, matrix 16x16, FOV 18-cm, 12-mm slice thickness) was undertaken using PRESS to define VOI. Spatially selective pulses, were placed at the edges of the VOI. Biopsies were collected intraoperatively and snap frozen in liquid nitrogen. 1D and 2D COSY spectra on biopsy material were acquired. Tissue was fixed using standard protocols and subtypes identified according to the WHO Histological Classification.

At 3T the MRI from a malignant ovarian mass shows the tumour clearly. The MR spectra shows choline, creatine, and lipid. 1D and 2D spectra obtained at 8.5T allow the 3T spectra to be directly compared with a data base of ovarian biopsies. The ex vivo (8.5T) and in vivo (3T) spectra from the tumor are very similar. In the 2D spectra the region 3.8-4.5 and 1.0-1.6ppm , shows cell surface fucosylation patterns consistent with level of de-differentiation. The independent histopathological diagnosis confirms the spectral diagnoses.

MRI and MRS (3T) can provide diagnostic information preoperatively on patients with ovarian masses. MRS at 8.5T on biopsies shows comparable spectral features to those obtained in vivo. 2D COSY shows level of de-differentiation of the tumours based on altered cell surface glycosylation.

C.M.,P.R.: We acknowledge that the Institute for Magnetic Resonance Research has a 20% shareholding in Sydney MRS. Dr Carolyn Mountford and Professor Peter Russell have a shareholding in the parent company, Sydney Magnetic Resonance Foundation.

Undertake in vivo spectroscopy and imaging of the ovary at 3T. This will be compared with spectroscopy at 8.5T done on biopsies collected intraoperatively.

Patients were recruited from the Gynaecological Oncology Unit at Royal North Shore Hospital. In vivo MR data was collected on a 3T Magnetom system (Siemens Germany) using a USA Instruments torso phased-array coil. Ovaries were identified on T2-weighted (TE/TR 98/4000ms, FOV 22-cm, matrix 266x512, 3-mm slice thickness, iPAT 2) axial and coronal images. 2D CSI (TE/TR 135/1380-ms, matrix 16x16, FOV 18-cm, 12-mm slice thickness) was undertaken using PRESS to define VOI. Spatially selective pulses, were placed at the edges of the VOI. Biopsies were collected intraoperatively and snap frozen in liquid nitrogen. 1D and 2D COSY spectra on biopsy material were acquired. Tissue was fixed using standard protocols and subtypes identified according to the WHO Histological Classification.

At 3T the MRI from a malignant ovarian mass shows the tumour clearly. The MR spectra shows choline, creatine, and lipid. 1D and 2D spectra obtained at 8.5T allow the 3T spectra to be directly compared with a data base of ovarian biopsies. The ex vivo (8.5T) and in vivo (3T) spectra from the tumor are very similar. In the 2D spectra the region 3.8-4.5 and 1.0-1.6ppm , shows cell surface fucosylation patterns consistent with level of de-differentiation. The independent histopathological diagnosis confirms the spectral diagnoses.

MRI and MRS (3T) can provide diagnostic information preoperatively on patients with ovarian masses. MRS at 8.5T on biopsies shows comparable spectral features to those obtained in vivo. 2D COSY shows level of de-differentiation of the tumours based on altered cell surface glycosylation.

C.M.,P.R.: We acknowledge that the Institute for Magnetic Resonance Research has a 20% shareholding in Sydney MRS. Dr Carolyn Mountford and Professor Peter Russell have a shareholding in the parent company, Sydney Magnetic Resonance Foundation.

Mountford, C, Stanwell, P, Ferrier, A, Bourne, R, Christie, J, Chin, R, Russell, P, et al, , In Vivo Spectroscopy of the Ovary at 3 Tesla.  Radiological Society of North America 2005 Scientific Assembly and Annual Meeting, November 27 - December 2, 2005 ,Chicago IL. http://archive.rsna.org/2005/4416108.html